About: The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro
Creator	Baba, Masanori Toyama, Masaaki Okamoto, Mika
Source	Elsevier; Medline; PMC
abstract	Cenicriviroc (CVC) is a small-molecule chemokine receptor antagonist with highly potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity through antagonizing C-C chemokine receptor type 5 (CCR5) as a coreceptor of HIV-1. CVC also strongly antagonizes C-C chemokine receptor type 2b (CCR2b), thereby it has potent anti-inflammatory and immunomodulatory effects. CVC is currently under clinical trials in the patients for treatment of nonalcoholic steatohepatitis, in which immune cell activation and dysregulation of proinflammatory cytokines play an important role in its pathogenesis. In this study, CVC was examined for its inhibitory effect on the replication of SARS-CoV-2, the causative agent of COVID-19, in cell cultures and found to be a selective inhibitor of the virus. The 50% effective concentrations of CVC were 19.0 and 2.9 μM in the assays based on the inhibition of virus-induced cell destruction and viral RNA levels in culture supernatants of the infected cells, respectively. Interestingly, the CCR5-specific antagonist maraviroc did not show any anti-SARS-CoV-2 activity. Although the mechanism of SARS-CoV-2 inhibition by CVC remains to be elucidated, CCR2b does not seem to be its target molecule. Considering the fact that the regulation of excessive immune activation is required to treat COVID-19 patients at the late stage of the disease, CVC should be further pursued for its potential in the treatment of SARS-CoV-2 infection.
has issue date	2020-07-30(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2020.104902
bibo:pmid	32739404
has license	no-cc
sha1sum (hex)	5ad42051521231441f2fcb0fb078d18dcc80cee6
schema:url	https://doi.org/10.1016/j.antiviral.2020.104902
resource representing a document's title	The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro
has PubMed Central identifier	PMC7392080
has PubMed identifier	32739404
schema:publication	Antiviral Res
resource representing a document's body	covid:5ad42051521231441f2fcb0fb078d18dcc80cee6#body_text
is schema:about of	named entity 'HIV-1' named entity 'Baba' named entity 'nonalcoholic steatohepatitis' named entity 'SARS-CoV-2' named entity 'maraviroc' named entity 'STUDY' named entity 'ROLE' named entity 'FOUND' named entity 'IMPORTANT' named entity 'selective' named entity 'cell' named entity 'levels' named entity 'specific' named entity 'study' named entity 'activity' named entity 'receptor antagonist' named entity 'potent' named entity 'antagonizes' named entity 'assays' named entity 'small-molecule' named entity 'cell cultures' named entity 'doi' named entity 'Toyama' named entity 'pathogenesis' named entity 'Antiviral Research' named entity 'anti-inflammatory' named entity 'maraviroc' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'remdesivir' named entity 'Bio-Rad' named entity 'Kyoto' named entity 'Kagoshima University' named entity 'infection' named entity 'nucleotide' named entity 'Abcam' named entity 'CCR2b' named entity 'ivermectin' named entity 'SARS-CoV-2' named entity 'bovine serum albumin' named entity 'HIV-1' named entity 'RNA virus' named entity 'CCR5' named entity 'multiplicity of infection' named entity 'CCR2b' named entity 'COVID' named entity 'standard deviation' named entity 'transcriptome' named entity 'antigen' named entity 'inflammation' named entity 'SARS-CoV-2' named entity 'hypoxia' named entity 'cell cultures' named entity 'G418' named entity 'SARS-CoV-2' named entity '37°C' named entity 'vaccines' named entity 'chloroquine' named entity 'anti-HIV' named entity 'hydrochloric acid' named entity 'cytokine' named entity 'hydroxychloroquine' named entity 'subnanomolar' named entity 'SARS-CoV-2' named entity 'virus' named entity 'cell culture' named entity 'nucleoside analogs' named entity 'cenicriviroc' named entity 'virus' named entity 'anti-HIV' named entity 'SARS-CoV-2' named entity 'systemic inflammation' named entity 'SARS-CoV-2' named entity 'Gene Expression' named entity 'SARS-CoV-2' named entity 'dimethyl sulfoxide' named entity 'morphological' named entity 'Japan'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software